EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients

Matthew Ringer iD, Maricar Malinis iD, Dayna McManus, Matthew Davis, Sunish Shah, Paul Trubin, Jeffrey E Topal, Marwan M Azar iD

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Matthew Ringer und 7 weiteren Autor:innen. Beteiligte Einrichtung: NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Influenza, Human, Thiepins, Dibenzothiepins, Morpholines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuraminidase inhibitors, including oseltamivir, are the treatment standard for influenza. Baloxavir, a novel antiviral, demonstrated comparable outcomes to oseltamivir in outpatients with influenza. Baloxavir was equally effective as oseltamivir in a retrospective study of hospitalized patients with influenza at our institution. However, the efficacy of baloxavir in immunocompromised patients is unclear.

Methods

We conducted a retrospective cohort study of immunocompromised adult patients hospitalized with influenza A who received baloxavir from January 2019 to April 2019 or oseltamivir from January 2018 to April 2018. Demographic and clinical outcomes were assessed. Primary outcomes were time from antiviral initiation to resolution of hypoxia and fever. Secondary outcomes were length of stay (LOS), intensive care unit (ICU) care, ICU LOS, and 30‐day mortality.

Results

Of 95 total patients, 52 received baloxavir and 43 received oseltamivir. Other than younger age (57.5 vs. 65; p = .035) and longer duration between vaccination and symptom onset (114 vs. 86 days; p = .001) in the baloxavir group, baseline characteristics did not differ. H1 was the predominant subtype in the baloxavir group (65.3%) versus H3 in the oseltamivir group (85.7%). When comparing baloxavir to oseltamivir, there was no significant difference in median time from antiviral initiation to resolution of hypoxia (59.9 vs. 42.5 h) and to resolution of fever (21.6 vs. 26.6 h). There were no differences in secondary outcomes.

Conclusion

Baloxavir was not associated with longer time to resolution of hypoxia or fever in comparison to oseltamivir. Results must be taken in context of variations in seasonal influenza subtype and resistance rates. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanThiepinsDibenzothiepinsMorpholinesPyridonesTriazinesAdultHumansOseltamivirRetrospective StudiesOxazinesPyridinesAntiviral AgentsImmunocompromised HostHypoxia

Stichwörter der Autor:innen

baloxavirimmunocompromisedinfluenzasolid‐organ transplant

Substanzen

OseltamivirbaloxavirOxazinesPyridinesThiepinsAntiviral AgentsDibenzothiepinsMorpholinesPyridonesTriazines

Autor:innen und Institutionen

  • NYU Grossman School of Medicine, New York, New York, USA.
  • NYU Langone Transplant Institute, New York, New York, USA.
  • Yale School of Medicine, Section of Infectious Disease, New Haven, Connecticut, USA.
  • Department of Pharmacy, Yale New Haven Hospital, New Haven, Connecticut, USA.
  • Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Matthew Ringer, Maricar Malinis, Marwan M Azar

Zitieren

APA

Ringer, M., Malinis, M., McManus, D., Davis, M., Shah, S., Trubin, P., Topal, J. E., & Azar, M. M. (2024). Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14249

Vancouver

Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, et al. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease. 2024. doi:10.1111/tid.14249

BibTeX
@article{Ringer2024,
  author = {Ringer, Matthew and Malinis, Maricar and McManus, Dayna and Davis, Matthew and Shah, Sunish and Trubin, Paul and Topal, Jeffrey E and Azar, Marwan M},
  title = {Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14249}
}
Kostenlos starten →